Soleno Therapeutics Inc (NASDAQ:SLNO) shares, rose in value on Wednesday, March 26, with the stock price down by -2.16% to the previous day’s close as strong demand from buyers drove the stock to $48.97.
Actively observing the price movement in the last trading, the stock closed the session at $50.05, falling within a range of $48.36 and $50.25. The value of beta (5-year monthly) was -1.694. Referring to stock’s 52-week performance, its high was $60.92, and the low was $36.61. On the whole, SLNO has fluctuated by 9.16% over the past month.
With the market capitalization of Soleno Therapeutics Inc currently standing at about $2.25 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SLNO’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the price of SLNO currently trading nearly 3.37% and 2.20% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 54.02, while the 7-day volatility ratio is showing 4.41% which for the 30-day chart, stands at 5.44%. Furthermore, Soleno Therapeutics Inc (SLNO)’s beta value is -2.12, and its average true range (ATR) is 2.35.
A comparison of Soleno Therapeutics Inc (SLNO) with its peers suggests the former has fared considerably weaker in the market. SLNO showed an intraday change of -2.16% in last session, and over the past year, it grew by 16.57%%.
Data on historical trading for Soleno Therapeutics Inc (NASDAQ:SLNO) indicates that the trading volumes over the past 10 days have averaged 0.84 and over the past 3 months, they’ve averaged 542.31K. According to company’s latest data on outstanding shares, there are 45.70 million shares outstanding.
Nearly 27.00% of Soleno Therapeutics Inc’s shares belong to company insiders and institutional investors own 90.83% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.99 million shares as on 2025-03-14, resulting in a short ratio of 8.63. According to the data, the short interest in Soleno Therapeutics Inc (SLNO) stood at 1611.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 4.54 million. The stock has risen by 8.94% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SLNO stock heading into the next quarter.
